IL17A and spondyloarthropathy: <h4>Objectives</h4>To investigate the dynamics of IL-17A levels in patients with spondyloarthritis (SpA) treated with secukinumab and to determine the relationship between circulating IL-17A forms and clinical response.<h4>Methods</h4>We analyzed serum IL-17A levels in 33 samples from 11 SpA patients using the highly sensitive proximity extension assay (PEA) at baseline and after 6 and 12 months of secukinumab treatment.